The recent FDA approval of a gene therapy for leukemia treatment marks a new frontier in medical innovation for the field of cancer immunotherapy. This two-day scientific symposium will explore cutting-edge findings in basic science, translational research, and clinical studies to improve immunotherapeutic approaches. Plenary speakers active in the fields of cancer biology, immunology, and cancer immunotherapy will present on an array of topics, including: new mechanistic perspectives from basic and preclinical research, results from early phase clinical trials of combination therapies, the durability of treatment responses to CAR-T cell therapies, and managing the known toxicity of effective immunotherapies in clinical trials.
Cancer Discussion Group at The New York Academy of Sciences
Jeffrey V. Ravetch, MD, PhD, The Rockefeller University
Miriam Merad, MD, PhD, Icahn School of Medicine at Mount Sinai
Call for Abstracts
Abstract submissions are invited for a poster session. The deadline for abstract submission is March 2, 2018.
The Cancer Research Institute is a promotional partner for this event.